A recent meta-analysis of the literature which included five randomized controlled trials encompassing 718 FGF21 assessments demonstrated the utility of FGF21 as a promising biomarker for mitochondrial disease diagnosis [130]. Here, FGF21 is linked to mitochondrial disease.